Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Rosen

Showing results (71-80 of 149) with videos related to

Pageof 15
Sort By:
Advances in Radiation Oncology|December 22, 2021
Toxicity and Efficacy After Adjuvant Vaginal Brachytherapy Using 30 Gy in 6 Fractions for Stages I and II Endometrial CancerJessica D Arden, Jonathan Dokter, Muayad F Almahariq, et al.
Gynecologic Oncology|September 12, 2006
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective studyMario E Beiner, Amy Finch, Barry Rosen, et al.
Gynecologic Oncology|November 8, 2015
A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancerGeneviève Bouchard-Fortier, Barry Rosen, Iryna Vyarvelska, et al.
Cancer|April 4, 2003
Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinomaDan A Grisaru, Allan Covens, Edmee Franssen, et al.
Metabolomics : Official Journal of the Metabolomic Society|March 5, 2019
Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot studyGunjal Garg, Ali Yilmaz, Praveen Kumar, et al.
American Journal of Clinical Oncology|August 10, 2020
Sequencing of Adjuvant Chemoradiation for Advanced Stage Endometrial Cancer: Outcomes and Toxicity ProfilesJessica D Arden, Kimberly Marvin, Sirisha R Nandalur, et al.
Biomed Research International|July 2, 2014
Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascitesTomer Feigenberg, Blaise Clarke, Carl Virtanen, et al.
Gynecologic Oncology|November 21, 2008
Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based studyKelly A Metcalfe, Isabel Fan, John McLaughlin, et al.
Cancer Causes & Control : CCC|March 17, 2015
Ovarian cancer survival by tumor dominance, a surrogate for site of originAnna Ivanova, Anneli Loo, Shelley Tworoger, et al.
British Journal of Cancer|June 17, 2022
Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancerJoanne Kotsopoulos, Neda Zamani, Barry Rosen, et al.
Pageof 15

Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
Advances in Radiation Oncology|December 22, 2021
Toxicity and Efficacy After Adjuvant Vaginal Brachytherapy Using 30 Gy in 6 Fractions for Stages I and II Endometrial CancerJessica D Arden, Jonathan Dokter, Muayad F Almahariq, et al.
Gynecologic Oncology|September 12, 2006
The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective studyMario E Beiner, Amy Finch, Barry Rosen, et al.
Gynecologic Oncology|November 8, 2015
A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancerGeneviève Bouchard-Fortier, Barry Rosen, Iryna Vyarvelska, et al.
Cancer|April 4, 2003
Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinomaDan A Grisaru, Allan Covens, Edmee Franssen, et al.
Metabolomics : Official Journal of the Metabolomic Society|March 5, 2019
Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot studyGunjal Garg, Ali Yilmaz, Praveen Kumar, et al.
American Journal of Clinical Oncology|August 10, 2020
Sequencing of Adjuvant Chemoradiation for Advanced Stage Endometrial Cancer: Outcomes and Toxicity ProfilesJessica D Arden, Kimberly Marvin, Sirisha R Nandalur, et al.
Biomed Research International|July 2, 2014
Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascitesTomer Feigenberg, Blaise Clarke, Carl Virtanen, et al.
Gynecologic Oncology|November 21, 2008
Uptake of clinical genetic testing for ovarian cancer in Ontario: a population-based studyKelly A Metcalfe, Isabel Fan, John McLaughlin, et al.
Cancer Causes & Control : CCC|March 17, 2015
Ovarian cancer survival by tumor dominance, a surrogate for site of originAnna Ivanova, Anneli Loo, Shelley Tworoger, et al.
British Journal of Cancer|June 17, 2022
Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancerJoanne Kotsopoulos, Neda Zamani, Barry Rosen, et al.
Pageof 15